Genfit shares clear their 11.46 € resistance ahead of today's results
The Lille-based biotech specialising in liver and metabolic diseases continues its rebound mid-session, in a Paris market trending higher. It ranks in the top part of the SBF 120 index and publishes its quarterly revenue today.
A resistance finally broken after a month of marked recovery
Genfit shares gain 2.51% to 11.42 € during the session, while the SBF 120 rises 0.52%.
The stock broke above its 11.46 € resistance intraday, a threshold the shares had not exceeded in recent weeks. It trades 7.13% above its 50-day moving average (MM50) and 20.08% above its 20-day moving average (MM20), a gap that illustrates the scale of the rebound since late October: +25.49% over one month, even though the three-month performance remains negative at -20.14%.
The move extends the gains of previous sessions, which had already placed the stock among the leaders of the index in early November. For reference, the biotech had fallen below 9 € on October 22 before rebounding.
Third-quarter revenue expected during the day
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
In a market where the CAC 40 rises 0.48%, the RSI at 61 still leaves room before the overbought zone, while the 7.83 € support level remains well below the share price.
Over one year, the stock shows a gain of 217.8%, a history that contrasts with the decline over the quarter. Today's results constitute the next concrete event for the stock.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 21,1 millions d'euros
Quarterly revenue: 21,1 millions d'euros
Net income: -26,1 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
